prnewswire.com
Cure8 news brief
Why This Matters
A market analysis listing late‑stage investigational therapies and growing use of IL‑23 and S1P pathway drugs signals potential new treatment options and changing prescribing patterns that may affect access, choice, and sequencing of IBD therapies.
Who Should Pay Attention
Patients with moderate‑to‑severe Crohn’s disease or ulcerative colitis, clinicians prescribing biologics, IBD researchers and drug developers, and health‑policy/market analysts.
Study Snapshot
Story typePress release
Evidence typeMarket or Business News
Source depthFull source text
What To Know
This press release describes a DelveInsight market report that forecasts IBD market growth through 2036, highlights late‑stage investigational drugs (for example ABX464/obefazimod, tulisokibart/MK‑7240, RHB‑204, TEV‑574/duvakitug), and emphasizes next‑generation mechanisms (IL‑23, TL1A, S1P).
It also notes expansion of IL‑23 inhibitors (mirikizumab, risankizumab, guselkumab) and continued use of anti‑TNF agents (adalimumab, infliximab). The report stresses unmet needs such as lack of predictive biomarkers and growing interest in precision/companion diagnostic approaches.
Keep In Mind
The source is a PR Newswire press release summarizing a DelveInsight market report. It is market‑focused and does not present new clinical trial data or peer‑reviewed evidence. Verify drug development status or efficacy claims using clinical trial registries or primary publications.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationprnewswire.com
PublisherCision PR Newswire
Indexed viaGoogle News
Source typeWeb article
PublishedJul 30, 2026, 2:39 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
J&J Q2 2026: Milvexian timeline, FireFly Bio acquisition, and H2 pipeline catalysts - AllSci
If you have IBD, J&J’s ICOTYDE/TREMFYA‑class program could expand oral IL‑23 treatment options for ulcerative colitis and Crohn’s disease and may have implications for perianal fistulizing Crohn’s disease — an area with...
'Reverse mergers are increasingly popular': Caldera hops on Synlogic's Nasdaq listing
Caldera’s funding and Nasdaq listing mean the company can run phase 2 trials in ulcerative colitis and Crohn’s disease of a bispecific drug that targets two immune pathways. If successful, that approach could change...
Biomerica Reports Second Quarter Fiscal 2025 Financial Results
At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...